Xilio Therapeutics, Inc. (XLO)Healthcare | Biotechnology | Waltham, United States | NasdaqCM
9.00 USD
+0.08
(0.897%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 9.02 +0.02 (0.222%) ⇧ (Aug. 28, 2026, 4:35 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 2:21 a.m. EDT
The immediate outlook remains flat due to a severe disconnect between the company's deteriorating financial reality and the optimistic analyst consensus. While a single analyst rates this as a 'strong buy' with a $20 target, the underlying data tells a different story: the stock has lost over 70% of its value over the last three years, driven by two consecutive years of significant declines (-21% and -68%). This multi-year trajectory suggests the market has already priced out the risks associated with the business model, rendering the bullish analyst call premature. Fundamentally, the company is burning through cash with negative operating margins and no revenue growth to speak of, despite a 131% reported revenue growth figure that likely reflects a base effect or one-time event rather than sustainable expansion. The balance sheet, while currently showing low debt, is propped up by cash reserves that are being consumed rapidly by operations. With no dividend to provide income and a price history indicating structural weakness, there is no compelling case for a near-term bounce or a long-term hold at these levels. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.025679 |
| AutoETS | 0.030618 |
| AutoTheta | 0.041670 |
| AutoARIMA | 0.057640 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 0.89 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.001 |
| Excess Kurtosis | 1.67 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 8.722 |
| Revenue per Share | 9.74 |
| Market Cap | 59,221,376 |
| Forward P/E | -15.52 |
| Beta | -0.12 |
| Profit Margins | -34.06% |
| Website | https://xiliotx.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.08713275 |
| Address1 | 828 Winter Street |
| Address2 | Suite 300 |
| All Time High | 391.3 |
| All Time Low | 6.468 |
| Ask | 11.9 |
| Ask Size | 2 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 11,100 |
| Average Daily Volume3 Month | 32,401 |
| Average Volume | 32,488 |
| Average Volume10Days | 11,100 |
| Beta | -0.119 |
| Bid | 6.48 |
| Bid Size | 2 |
| Book Value | 7.785 |
| City | Waltham |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 9.0 |
| Current Ratio | 4.254 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 9.0001 |
| Day Low | 8.995 |
| Debt To Equity | 8.722 |
| Display Name | Xilio Therapeutics |
| Earnings Timestamp End | 1,754,911,858 |
| Earnings Timestamp Start | 1,754,479,858 |
| Ebitda | -30,030,000 |
| Ebitda Margins | -0.46855 |
| Enterprise To Ebitda | 2.348 |
| Enterprise To Revenue | -1.1 |
| Enterprise Value | -70,515,624 |
| Eps Forward | -0.58 |
| Eps Trailing Twelve Months | -0.32 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 9.0782 |
| Fifty Day Average Change | -0.07820034 |
| Fifty Day Average Change Percent | -0.00861408 |
| Fifty Two Week Change Percent | -8.061224 |
| Fifty Two Week High | 12.74 |
| Fifty Two Week High Change | -3.7399998 |
| Fifty Two Week High Change Percent | -0.29356357 |
| Fifty Two Week Low | 6.468 |
| Fifty Two Week Low Change | 2.532 |
| Fifty Two Week Low Change Percent | 0.3914657 |
| Fifty Two Week Range | 6.468 - 12.74 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,634,909,400,000 |
| Float Shares | 3,402,531 |
| Forward Eps | -0.58 |
| Forward P E | -15.5172415 |
| Free Cashflow | -37,562,000 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 76 |
| Fullday Change | 0.0799999 |
| Fullday Change Percent | 0.89686 |
| Fullday Price | 9.02 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.83156997 |
| Gross Profits | 53,297,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.25982 |
| Held Percent Institutions | 0.50136 |
| Implied Shares Outstanding | 6,580,153 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-10-22 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,773,619,200 |
| Last Split Factor | 1:14 |
| Long Business Summary | Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts. |
| Long Name | Xilio Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 59,221,376 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_365333564 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -21,829,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 58,694,964 |
| Number Of Analyst Opinions | 1 |
| Open | 8.995 |
| Operating Cashflow | -60,598,000 |
| Operating Margins | -0.18676001 |
| Payout Ratio | 0.0 |
| Phone | 857 524 2466 |
| Post Market Change | 0.020000458 |
| Post Market Change Percent | 0.2222273 |
| Post Market Price | 9.02 |
| Post Market Time | 1,787,949,322 |
| Previous Close | 8.92 |
| Price Hint | 2 |
| Price To Book | 1.1560694 |
| Price To Sales Trailing12 Months | 0.92400575 |
| Profit Margins | -0.34058997 |
| Quick Ratio | 4.153 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 0.07999992 |
| Regular Market Change Percent | 0.8968601 |
| Regular Market Day High | 9.28 |
| Regular Market Day Low | 8.995 |
| Regular Market Day Range | 8.995 - 9.28 |
| Regular Market Open | 8.995 |
| Regular Market Previous Close | 8.92 |
| Regular Market Price | 9.0 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 3,530 |
| Return On Assets | -0.13611001 |
| Return On Equity | -0.55030996 |
| Revenue Growth | 1.312 |
| Revenue Per Share | 9.74 |
| Sand P52 Week Change | 0.1966995 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 6,580,153 |
| Shares Percent Shares Out | 0.0641 |
| Shares Short | 421,921 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 268,180 |
| Short Name | Xilio Therapeutics, Inc. |
| Short Percent Of Float | 0.0716 |
| Short Ratio | 13.74 |
| Source Interval | 15 |
| State | MA |
| Symbol | XLO |
| Target High Price | 20.0 |
| Target Low Price | 20.0 |
| Target Mean Price | 20.0 |
| Target Median Price | 20.0 |
| Total Cash | 136,040,000 |
| Total Cash Per Share | 20.674 |
| Total Debt | 6,303,000 |
| Total Revenue | 64,092,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.32 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 8.745045 |
| Two Hundred Day Average Change | 0.2549553 |
| Two Hundred Day Average Change Percent | 0.029154258 |
| Type Disp | Equity |
| Volume | 3,530 |
| Website | https://xiliotx.com |
| Zip | 2,451 |